If you didn't find what you were looking for, try a new search!
The American Academy of Sleep Medicine (AASM) is inviting public comment on drafts of a clinical practice guideline on the Behavioral and Psychological Treatments for Chronic Insomnia Disorder in Adults and accompanying systematic review. The public comment period is open for 4 weeks [...]
The U.S. Food and Drug Administration has cleared the first prescription-based digital therapeutic for the treatment of chronic insomnia in adults, according to a press release from the product developer, Pear Therapeutics. Somryst, formerly SHUTi, uses cognitive behavioral therapy and data-based sleep restrictions to [...]
Merck announced Feb. 3, 2020, that the U.S. Food and Drug Administration has updated the prescribing information for Belsomra (suvorexant) to include details about an insomnia study in patients with mild to moderate Alzheimer’s disease. Belsomra was first FDA-approved for the treatment of insomnia [...]
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced that the U.S. Food and Drug Administration has approved Dayvigo (lemborexant) 5 mg and 10 mg for the treatment of adult patients with sleep-onset insomnia and sleep maintenance insomnia. According to Eisai, the [...]
Insomnia in Children Health Advisory Behavioral interventions should be the first treatment option for healthy children who struggle with bedtime resistance or nighttime awakenings. For those who fail to respond, or for children with more complex medical problems, evaluation by a sleep physician [...]
Question: What code is used for cognitive behavioral therapy for insomnia (CBT-I)? Answer: There are three different code series that can be used to report cognitive behavioral therapy for insomnia (CBT-I). Some providers report evaluation and management (E/M) codes for new and established patients, [...]
SAN ANTONIO – Preliminary findings from two analyses of an ongoing study suggest that cognitive behavioral therapy for insomnia delivered by telemedicine is as effective as face-to-face delivery. Results of a randomized controlled non-inferiority trial show that both delivery methods were equally effective [...]
According to a safety announcement and consumer update issued April 30, the U.S. Food and Drug Administration is requiring the addition of a boxed warning to the prescribing information and the patient medication guides for the insomnia medications eszopiclone (Lunesta), zaleplon (Sonata), and zolpidem [...]
DARIEN, IL – Monday, March 11, is the sixth annual Insomnia Awareness Day, organized by the American Academy of Sleep Medicine (AASM), Society of Behavioral Sleep Medicine (SBSM) and American Alliance for Healthy Sleep (AAHS). This year’s theme is “Solutions for Sleepless Nights,” highlighting [...]
DARIEN, IL – A new study is the first population-based investigation to report a significant association between artificial, outdoor light exposure at night and insomnia, as indicated by older adults’ use of hypnotic drugs. Results show that increasing nighttime levels of artificial, outdoor light [...]
DARIEN, IL – Preliminary findings from a pilot study suggest that cognitive behavioral therapy for insomnia (CBT-I) may slow or even reverse the atrophy of cortical gray matter in patients who have co-morbid fibromyalgia. Results suggest that eight weeks of CBT-I can alter central [...]
BALTIMORE – Preliminary results from a new study indicate that greater amounts of daily screen time are associated with more insomnia symptoms and shorter sleep duration among adolescents. Results show that for social messaging, web surfing and TV/movie watching, insomnia symptoms and sleep duration [...]
Currently practicing at Virginia Mason Medical Center, Dr. Brandon Peters is boardcertified in sleep medicine and neurology. His published research includes studies of sleep ethics, the sleep habits of university students, circadian rhythm disorders in the blind, and parasomnias. With a goal [...]
A must read for any sleep professional Whether you are seasoned in sleep medicine or new to the field, you will gain a better understanding of insomnia by reading this free e-book. Download it today to learn more about one [...]
Earlier this week the Agency for Healthcare Research and Quality released a research summary for clinicians, Management of Insomnia Disorder in Adults: Current State of the Evidence, which highlights findings from an AHRQ-funded evidence review.
Preliminary results from a new study show that depressed patients with insomnia who sleep seven or more hours per night are more likely to benefit from cognitive behavioral therapy for insomnia (CBTI) and achieve depression remission.
Preliminary results from a new study show that partners of people who have insomnia may try to be supportive by engaging in a range of behaviors that unintentionally contradict treatment recommendations.
Monday, March 13, is the fourth annual Insomnia Awareness Day, which was instituted by the American Academy of Sleep Medicine (AASM) to bring attention to this common sleep disorder.
Computer-based delivery of cognitive behavioral therapy for insomnia (CBT-I) improves sleep in individuals with insomnia and co-occurring mental illness, according to a study in the February issue of the Journal of Clinical Sleep Medicine.
A new clinical practice guideline is the first from the American Academy of Sleep Medicine to provide comprehensive, evidence-based analyses of individual agents commonly used in the treatment of chronic insomnia disorder.
Patients with insomnia, regardless of OSA status, have lower sleep perception and showed smaller discrepancy between objective sleep time and habitual sleep duration compared to patients with OSA or good sleepers, suggests a new study in the November 15 issue of the Journal of Clinical Sleep Medicine.
A study in the September issue of the Journal of Clinical Sleep Medicine suggests that suvorexant 20/15 mg improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated.
A study in the August issue of the Journal of Clinical Sleep Medicine suggests that the Pittsburgh Sleep Quality Index (PSQI) may be a good screening tool for insomnia in a college population.
According to a new study, child adversities, which are known to play an important role in mental and physical health, are also associated with poor sleep.
The U.S. Food and Drug Administration (FDA) has granted commercial clearance for the Cerêve Sleep System, a prescription device that reduces latency to Stage 1 and Stage 2 sleep for people with insomnia, according to a company press release.
A new study sheds light on the prevalence of insomnia symptoms among female veterans.
Based on the premise that insomnia can be lonely, a new study from South Korea found that thwarted belongingness significantly accounted for the relationship between insomnia severity and suicidal ideation.
Among adult volunteers meeting current diagnostic criteria for insomnia disorder, objectively measured short sleep duration increased the odds of reporting hypertension more than threefold, according to a study published in the May issue of the journal SLEEP.
A study in the May issue of the journal SLEEP is the first to show that adolescents who complain of insomnia have increased fast frequencies in the electroencephalogram while trying to fall asleep or while asleep, and these levels were highest in those with short sleep duration.
The American Academy of Sleep Medicine (AASM) is inviting public comment on a draft clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. Comments must be submitted by May 13, 2016.
The American Academy of Sleep Medicine (AASM) is recognizing the third annual Insomnia Awareness Day on Monday, March 14, as the “spring forward” shift to daylight saving time creates the potential for another lost hour of sleep, adding to the already enormous cost of untreated insomnia.
A study published in the March issue of the journal SLEEP shows that insomnia is associated with shorter peripheral blood mononuclear cells (PBMC) telomere length in adults between 70 and 88 years of age, suggesting that clinically severe sleep disturbances may increase cellular aging, especially in the later years of life.